Current practices and guidelines for clinical next-generation sequencing oncology testing

Next-generation sequencing (NGS) has been rapidly integrated into molecular pathology, dramatically increasing the breadth genomic of information available to oncologists and their patients. This review will explore the ways in which this new technology is currently applied to bolster care for patie...

Descripción completa

Detalles Bibliográficos
Autor principal: Strom, Samuel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Anti-Cancer Association 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850126/
https://www.ncbi.nlm.nih.gov/pubmed/27144058
http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0004
_version_ 1782429620116652032
author Strom, Samuel P.
author_facet Strom, Samuel P.
author_sort Strom, Samuel P.
collection PubMed
description Next-generation sequencing (NGS) has been rapidly integrated into molecular pathology, dramatically increasing the breadth genomic of information available to oncologists and their patients. This review will explore the ways in which this new technology is currently applied to bolster care for patients with solid tumors and hematological malignancies, focusing on practices and guidelines for assessing the technical validity and clinical utility of DNA variants identified during clinical NGS oncology testing.
format Online
Article
Text
id pubmed-4850126
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Chinese Anti-Cancer Association
record_format MEDLINE/PubMed
spelling pubmed-48501262016-05-03 Current practices and guidelines for clinical next-generation sequencing oncology testing Strom, Samuel P. Cancer Biol Med Review Next-generation sequencing (NGS) has been rapidly integrated into molecular pathology, dramatically increasing the breadth genomic of information available to oncologists and their patients. This review will explore the ways in which this new technology is currently applied to bolster care for patients with solid tumors and hematological malignancies, focusing on practices and guidelines for assessing the technical validity and clinical utility of DNA variants identified during clinical NGS oncology testing. Chinese Anti-Cancer Association 2016-03 /pmc/articles/PMC4850126/ /pubmed/27144058 http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0004 Text en Copyright 2016 Cancer Biology & Medicine http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Review
Strom, Samuel P.
Current practices and guidelines for clinical next-generation sequencing oncology testing
title Current practices and guidelines for clinical next-generation sequencing oncology testing
title_full Current practices and guidelines for clinical next-generation sequencing oncology testing
title_fullStr Current practices and guidelines for clinical next-generation sequencing oncology testing
title_full_unstemmed Current practices and guidelines for clinical next-generation sequencing oncology testing
title_short Current practices and guidelines for clinical next-generation sequencing oncology testing
title_sort current practices and guidelines for clinical next-generation sequencing oncology testing
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4850126/
https://www.ncbi.nlm.nih.gov/pubmed/27144058
http://dx.doi.org/10.28092/j.issn.2095-3941.2016.0004
work_keys_str_mv AT stromsamuelp currentpracticesandguidelinesforclinicalnextgenerationsequencingoncologytesting

Ejemplares similares